BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11384581)

  • 1. Washout periods for brimonidine 0.2% and latanoprost 0.005%.
    Stewart WC; Holmes KT; Johnson MA
    Am J Ophthalmol; 2001 Jun; 131(6):798-9. PubMed ID: 11384581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
    DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
    Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study.
    Kampik A; Arias-Puente A; O'Brart DP; Vuori ML;
    J Glaucoma; 2002 Apr; 11(2):90-6. PubMed ID: 11912355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
    Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic success of latanoprost 0.005% compared to brimonidine 0.2% in patients with open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Holmes KT; Leech JN; Rowan CT; Schwartz GF
    J Ocul Pharmacol Ther; 2000 Dec; 16(6):557-64. PubMed ID: 11132902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in intraocular pressure and ocular perfusion pressure after latanoprost 0.005% or brimonidine tartrate 0.2% in normal-tension glaucoma patients.
    Liu CJ; Ko YC; Cheng CY; Chiu AW; Chou JC; Hsu WM; Liu JH
    Ophthalmology; 2002 Dec; 109(12):2241-7. PubMed ID: 12466165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison between latanoprost and brimonidine efficacy and safety in Indian eyes.
    Thomas R; Parikh R; Muliyil J; George R; Paul P; Abraham LM
    Indian J Ophthalmol; 2003 Jun; 51(2):123-8. PubMed ID: 12831141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Latanoprost and brimonidine: therapeutic and physiologic assessment before and after oral nonsteroidal anti-inflammatory therapy.
    Sponsel WE; Paris G; Trigo Y; Pena M; Weber A; Sanford K; McKinnon S
    Am J Ophthalmol; 2002 Jan; 133(1):11-8. PubMed ID: 11755835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension.
    Stewart WC; Sharpe ED; Day DG; Kolker AE; Konstas AG; Lee WH; Rieser JC; Chopra H; Holmes KT
    J Ocul Pharmacol Ther; 2000 Jun; 16(3):251-9. PubMed ID: 10872922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy.
    Stewart WC; Stewart JA; Day DG; Sharpe ED; Jenkins JN
    Eye (Lond); 2004 Oct; 18(10):990-5. PubMed ID: 15037890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial.
    Lee DA; Gornbein JA
    J Glaucoma; 2001 Jun; 10(3):220-6. PubMed ID: 11442187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation and comparison between the effects on intraocular pressure and retinal blood flow of two antiglaucomatous drugs administered in monotherapy: brimonidine and latanoprost. Preliminary results.
    Rolle T; Cipullo D; Vizzeri GM; Triggiani A; Brogliatti B
    Acta Ophthalmol Scand Suppl; 2000; (232):50-2. PubMed ID: 11235536
    [No Abstract]   [Full Text] [Related]  

  • 13. Fixed-combination brimonidine-timolol versus latanoprost in glaucoma and ocular hypertension: a 12-week, randomized, comparison study.
    Katz LJ; Rauchman SH; Cottingham AJ; Simmons ST; Williams JM; Schiffman RM; Hollander DA
    Curr Med Res Opin; 2012 May; 28(5):781-8. PubMed ID: 22458918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of latanoprost and brimonidine on blood flow velocity of the retrobulbar vessels: a 3-month clinical trial.
    Inan UU; Ermis SS; Yücel A; Oztürk F
    Acta Ophthalmol Scand; 2003 Apr; 81(2):155-60. PubMed ID: 12752054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects.
    Konstas AG; Karabatsas CH; Lallos N; Georgiadis N; Kotsimpou A; Stewart JA; Stewart WC
    Ophthalmology; 2005 Apr; 112(4):603-8. PubMed ID: 15808251
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-masked randomized crossover study comparing the effect of latanoprost/timolol and brimonidine/timolol fixed combination on intraocular pressure and ocular blood flow in patients with primary open-angle glaucoma or ocular hypertension.
    Hommer A; Sperl P; Resch H; Popa-Cherecheanu A; Qiao C; Schmetterer L; Garhöfer G
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):569-75. PubMed ID: 22775229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brimonidine and latanoprost as adjunctive therapy.
    Camras CB
    Ophthalmology; 2003 Jan; 110(1):6-8; author reply 8-9. PubMed ID: 12511334
    [No Abstract]   [Full Text] [Related]  

  • 18. Initial medical management of open-angle glaucoma.
    Fechtner RD
    J Glaucoma; 2000 Feb; 9(1):83-6. PubMed ID: 10708236
    [No Abstract]   [Full Text] [Related]  

  • 19. Additive intraocular pressure lowering effect of various medications with latanoprost.
    O'Connor DJ; Martone JF; Mead A
    Am J Ophthalmol; 2002 Jun; 133(6):836-7. PubMed ID: 12036683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension.
    Orzalesi N; Rossetti L; Bottoli A; Fumagalli E; Fogagnolo P
    Arch Ophthalmol; 2003 Apr; 121(4):453-7. PubMed ID: 12695241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.